kyvernatx.com - KYTX Aggregate Business Value
Kyverna Therapeutics (KYTX) is developing unique CAR-T solutions to combat severe systemic pathologies, avoiding price competition due to a lack of direct analogs. Business revenues will be based on the market launch of personalized T-cell products targeting sclerosis and lupus. This price chart, showing an enterprise value of 184.22, complements data regarding California laboratories and a network of manufacturing partners.
Kyverna Therapeutics (KYTX) - metric breakdowns and financial figures
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Kyverna Therapeutics|KYTX - Long-Term Debt to Capital|Short-Term Debt to Capital kyvernatx.com|KYTX - Company Debts|Debt to Net Assets Ratio Kyverna Therapeutics|KYTX - Company Long-Term Debt|Company Current Liabilities Kyverna Therapeutics|Quick Ratio kyvernatx.com
- earnings and valuation multiples indicators:
Analysis of all company metrics:Kyverna Therapeutics Inc.
Inelastic demand for a unique CAR-T lupus therapy provides Kyverna Therapeutics (KYTX) with significant pricing power, which directly impacts the EV trend. This indicator aggregates market capitalization and debt, minus cash, to determine the actual cost of a full business buyout, allowing investors to assess the real scale of the enterprise without liquidity distortions.
Competitors of Kyverna Therapeutics (KYTX)
argenx N.V. (ARGX) - Total Enterprise Value|BNTX: Real Price to Acquire Entire Company|Abivax Pharma - Aggregate Business Value|ADMA (ADMA Biologics) - Real Price to Acquire Entire Company|Business Value PTGX|Total Company Value Immunovant|Kiniksa Pharmaceuticals, Ltd. - Full Business Value|Enterprise Value GRFS|ADPT (Adaptive Biotechnologies Inc.) - Value Adjusted for Debt and Cash|Enterprise Value CLDX (Celldex Therapeutics)|Enterprise Value auriniapharma.com AUPH|BCRX - Total Company Value|Value Adjusted for Debt and Cash VERA (Vera Therapeutics Inc)|Dianthus Pharma (DNTH) - Total Company Value|Real Price to Acquire Entire Company Pharvaris Pharma|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com|Real Price to Acquire Entire Company PGEN (Precigen)|PHAR (Pharming Group NV) - Value Adjusted for Debt and Cash|Enterprise Value NKTR (Nektar)|Company Buyout Price Upstream Pharma (UPB)|ZBIO - Total Company Value|immunome.com (IMNM) - Real Price to Acquire Entire Company|Gossamer Bio (GOSS) - Total Company Value|Real Price to Acquire Entire Company KalVista Pharma|Real Price to Acquire Entire Company SEPN|Enterprise Value Pieris Corp|Total Company Value Savara Inc. (SVRA)|rigel.com - Business Value|Enterprise Value ANAB (AnaptysBio)|Astria Therapeutics Inc (ATXS) - Total Enterprise Value|ENGN - Total Company Value|RAPT - Enterprise Value|JBIO (aerovatetx.com) - Real Price to Acquire Entire Company|Total Enterprise Value aclaristx.com (ACRS)|Real Price to Acquire Entire Company TLSA|Total Company Value CABA|Enterprise Value VTYX|THTX - Total Enterprise Value|Total Company Value Avalo Therapeutics, Inc AVTX|Value Adjusted for Debt and Cash ELDN|AGEN - Total Company Value|CLYM (Climb Bio Inc.) - Business Value|ZURA: Enterprise Value|aTyr Pharmaceuticals (ATYR) - Enterprise Value|Real Price to Acquire Entire Company ADAG|IMA: Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company STTK (Shattuck Labs, Inc.)|Aggregate Business Value EQ|Enterprise Value CNTB (Connect Biopharma Holdings Limited)|Value Adjusted for Debt and Cash IMUX|Atara Biotherapeutics Inc - Enterprise Value|Total Enterprise Value InflaRx N.V.|X4 Pharmaceuticals, Inc. (XFOR) - Total Company Value|Adicet Bio, Inc. - Value Adjusted for Debt and Cash|CELU (Celularity Inc) - Enterprise Value|Enterprise Value INmune Bio Corporation|Total Company Value Barinthus Biotherapeutics (BRNS)|KZR: Full Business Value|Enterprise Value SABS (SAB Biotherapeutics, Inc.)|Akari Therapeutics PLC (AKTX) - Total Enterprise Value|ENLV: Real Price to Acquire Entire Company|QTTB - Enterprise Value|GOVX (GeoVax Labs, Inc.) - Real Price to Acquire Entire Company|EDSA: Aggregate Business Value|IBIO (iBio) - Enterprise Value|Carisma Tx (CARM) - Company Buyout Price|Enterprise Value XTLB|Real Price to Acquire Entire Company boltbio.com BOLT|Total Company Value HCW Biologics HCWB|Company Buyout Price Aptevo Therapeutics, Inc. (APVO)|AIM - Total Company Value|ADTX - Enterprise Value|GRI (GRI Bio Corp) - Real Price to Acquire Entire Company|Total Enterprise Value XORTX Corp (XRTX)|Real Price to Acquire Entire Company HIND|REVB (revbiosciences.com) - Aggregate Business Value|Real Price to Acquire Entire Company INDP (Indaptus Therapeutics, Inc.)|Scinai Immunotherapeutics Ltd - Business Value|Total Company Value CalciMedica CALI|AFMD (Affimed NV) - Full Business Value|Allakos Therapeutics - Enterprise Value|Value Adjusted for Debt and Cash HOOK (HOOKIPA Pharma Inc.)|IGMS: Enterprise Value|iTeos Therapeutics Inc (ITOS) - Enterprise Value|Total Company Value Ocean Bio|TCBP: Value Adjusted for Debt and Cash|Total Company Value Third Harmonic Bio (THRD)